The 3rd Joint Session between TDDW - JDDW – KDDW
September 28, 2019（Saturday）16:00-17:40
Kaohsiung Exhibition Center (Conference Room D, 301b)
Kaohsiung Exhibition Center (Conference Room D, 301b)
Optimization of direct anti-viral agent treatment for HCV: Current status in the Asia-Pacific region
* you can left or right swipe programme.
| Time | Topic | Speaker |
|---|---|---|
|
Jia-Horng Kao
(Taiwan) Namiki Izumi (Japan) Sook Hyang Jeong (Korea) |
||
|
Chun-Yen Lin
(Taiwan) Yoshihito Uchida (Japan) Jong Eun Yeon (Korea) |
||
| Sofosbuvir-based direct acting antivirals: to renal injury or not? | Chen-Hua Liu
(Taiwan)
|
|
| Optimizing DAA treatment for chronic hepatitis C - Lessons from Japanese experience | Tatsuya Kanto
(Japan)
|
|
| Past and current status of DAA therapy for CHC in Korea | Jung Hyun Kwon
(Korea)
|
|
| Rising star | ||
| New biomarkers in predicting HCC development in CHB patients | Tai-Chung Tseng
(Taiwan)
|
|
| Treatment of hepatitis C in special populations | Goki Suda
(Japan)
|
|
| How to enhance the efficacy of systemic therapies for HCC | Su Jong Yu
(Korea)
|
|
* you can left or right swipe programme.
＊Sessions：20 minute lecture/ per speaker (Oral 15 mins, Q&A 5 mins)
＊Rising Star Program：10 minute lecture/ per speaker (Oral 7 mins, Q&A 3 mins)
＊Rising Star Program：10 minute lecture/ per speaker (Oral 7 mins, Q&A 3 mins)